Next Article in Journal
Designing Inclusive HPV Cancer Vaccines and Increasing Uptake among Native Americans—A Cultural Perspective Review
Next Article in Special Issue
Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer
Previous Article in Journal
Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy
Previous Article in Special Issue
Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 28
Issue 5
10.3390/curroncol28050315
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

by
Tim Wollenweber
1,
Lucia Zisser
1,
Elisabeth Kretschmer-Chott
1,
Michael Weber
2,
Bernhard Grubmüller
3,
Gero Kramer
3,
Shahrokh F. Shariat
3,4,5,6,7,
Markus Mitterhauser
1,8,
Stefan Schmitl
1,
Chrysoula Vraka
1,
Alexander R. Haug
1,9,
Marcus Hacker
1,
Markus Hartenbach
1 and
Sazan Rasul
1,*
1
Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
2
Department of Biomedical Imaging and Image-guided Therapy, Division of General Radiology, Medical University of Vienna, 1090 Vienna, Austria
3
Department of Urology, Medical University of Vienna, 1090 Vienna, Austria
4
Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA
5
Department of Urology, Second Faculty of Medicine, Charles University, 15006 Prague, Czech Republic
6
Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia
7
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
8
Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria
9
Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Medical University of Vienna, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 3692-3704; https://doi.org/10.3390/curroncol28050315
Submission received: 1 September 2021 / Revised: 18 September 2021 / Accepted: 21 September 2021 / Published: 23 September 2021
(This article belongs to the Collection New Insights into Prostate Cancer Diagnosis and Treatment)
Browse Figures
Versions Notes

Abstract

Background: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary [68Ga]Ga-PSMA-11 ligand PET scan measures such as metabolic volume and SUVmax values of 27 mCRPC men (mean age 71 ± 7 years) before and 4 weeks after receiving three cycles of PSMA-RLT every 4 weeks. Twenty-two patients additionally obtained renal and salivary scintigraphy prior to each cycle. A one-way ANOVA, post-hoc Scheffé test and Cochran’s Q test were applied to assess organ toxicity. Results: In total, 54 PSMA PET scans, 98 kidney, and 98 salivary scintigraphy results were evaluated. There were no significant differences for the ejection fraction, peak time, and residual activity after 5 min for both parotid and submandibular glands prior to each cycle and 4 weeks after the last cycle. Similarly, no significant differences in serum creatinine and renal scintigraphy parameters were observed prior to each cycle and 4 weeks after the last treatment. Despite there being no changes in the metabolic volume of both submandibular glands, SUVmax values dropped significantly (p < 0.05). Conclusion: Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks.
Keywords: PSMA; prostate cancer; mCRPC; renal scintigraphy; salivary scintigraphy PSMA; prostate cancer; mCRPC; renal scintigraphy; salivary scintigraphy

Share and Cite

MDPI and ACS Style

Wollenweber, T.; Zisser, L.; Kretschmer-Chott, E.; Weber, M.; Grubmüller, B.; Kramer, G.; Shariat, S.F.; Mitterhauser, M.; Schmitl, S.; Vraka, C.; et al. Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Curr. Oncol. 2021, 28, 3692-3704. https://doi.org/10.3390/curroncol28050315

AMA Style

Wollenweber T, Zisser L, Kretschmer-Chott E, Weber M, Grubmüller B, Kramer G, Shariat SF, Mitterhauser M, Schmitl S, Vraka C, et al. Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Current Oncology. 2021; 28(5):3692-3704. https://doi.org/10.3390/curroncol28050315

Chicago/Turabian Style

Wollenweber, Tim, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka, and et al. 2021. "Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer" Current Oncology 28, no. 5: 3692-3704. https://doi.org/10.3390/curroncol28050315

APA Style

Wollenweber, T., Zisser, L., Kretschmer-Chott, E., Weber, M., Grubmüller, B., Kramer, G., Shariat, S. F., Mitterhauser, M., Schmitl, S., Vraka, C., Haug, A. R., Hacker, M., Hartenbach, M., & Rasul, S. (2021). Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Current Oncology, 28(5), 3692-3704. https://doi.org/10.3390/curroncol28050315

Article Metrics

Back to TopTop